TW509689B - Benzothiadiazoles and derivatives - Google Patents

Benzothiadiazoles and derivatives Download PDF

Info

Publication number
TW509689B
TW509689B TW088102726A TW88102726A TW509689B TW 509689 B TW509689 B TW 509689B TW 088102726 A TW088102726 A TW 088102726A TW 88102726 A TW88102726 A TW 88102726A TW 509689 B TW509689 B TW 509689B
Authority
TW
Taiwan
Prior art keywords
alkyl
patent application
scope
compound
propyl
Prior art date
Application number
TW088102726A
Other languages
English (en)
Inventor
Bernhard Peter Neumann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of TW509689B publication Critical patent/TW509689B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)

Description

509689 五、發明說明（1) 本發明係有關新穎之苯并噻二哇及衍生物，其製法，其 使用作為醫藥之用途及含其之醫藥組合物。 . 詳言之，本發明提供一種呈游離鹼或酸加成鹽態之式I 化合物：
Het 其中 X 為0，S，N-CH3，CH = CH 或 CAlk = CAlk，其中 Aik 獨立為 ((^_4)烧基， K及1獨立為氫、鹵素、（C!_4)烷基、（C^)烷氧基或三氟甲 基；及
Het為具下式（a)至（p)之一之基：
第4頁 509689 五、發明說明.(2)
⑽ ⑻ ⑹ （p) 其中 R3&R8獨立為氮或（（^_4)烧基’ R4為氫、鹵素、（CV4)烷基、氰基、硝基、甲醯基或（CV4) 烷羰基， R5及1獨立為氫、（Ch)烷基、（c3_7)烯基、（c3_?)環烷基、 (c3_7)環烷基（Ch)院基、（(ν4)烷氧基（c2_5)烷基或1基， R7為氫、羥基、（(^_4)烷基或（Ch)烷氧基， W 為N，C-CN，C'N02，C-C0H 或 C-C〇-Alk，其中 Aik 如上述 定義’及 X如上述定義。 鹵素為氟、氣、漠或蛾，較好為氟或氣。
Het基較好位於與式I雜環部份鄰接之碳原子上。較好 Het為式（a)至（k)，尤其是式（a)。 進一步目的中，本發明提供一種製備式I化合物及其鹽
第5頁 509689
第6頁 509689 五、發明說明（4)
其中R3至1，W及X如前述定義及Hal為鹵素；與式II I化合 物反應：
HN\ III
Rs 其中R5及{?6如前述定義；及使所得化合物轉化成游離鹼態 或酸加成鹽態。 反應可以已知方式如實例1所述般進行。Ha 1較好為氣、-漠或蛾，尤其是氯。 上述方法所得反應混合物之結束反應操作及所得化合物 之純化可依據已知程序進行。 酸加成鹽可依已知方式自游離鹼製得或相反。用於本發 明之適宜醫藥可接受性酸加成鹽包含例如鹽酸鹽、馬來酸 氫鹽、富馬酸氫鹽及丙二酸氫鹽。 式I I起始物可如下製得： 其中Y為具式（a’）至（d’）之一之基之式II化合物之獲得 可藉使式IV化合物： ’
第7頁 509689
第8頁 509689 五、發明說明（6) 其中R3、R4、R7、r8及^如前述定義。 所有前述反應為習知。 ， 式I I I ’ I V ’ V a ’ V d及V I化合物為已知或可由已知化合 物使用習知程序製得。 式I化合物及其醫藥可接受性酸加成鹽（後文稱為本發明 藥劑）當使用促腎皮素釋出因子（CRF)受體表現細胞培養基 於體外測式及於動物中測試時，呈現有價值之醫藥性質， 且因此可作為醫藥。 尤其’本發明試藥結合至CRF受體上。詳言之，其呈現 以下列分析於活體外測定之對⑶匕受體之拮抗活性： 中國田鼠妒巢（CH0)細胞表現人類重組體CRF, (Chen等 人，Proc Natl Acad Sci USA 90， 8967-8971， 1993)於 補充有10%胎牛血清、非必需胺基酸、丨00 (]/毫升青黴 素、100毫克/升鏈黴素及1克/升基因素（genet i cin) (G418)之杜貝可（Dulbecco’s)改質之鷹培養基中繁殖。對 環狀AMP測定而言，細胞於2 4-洞盤中生長群集。如前述 (Schoeffter 等人，神經醫學 36， 42 9-437， 1 99 7 )使用 PH]腺嘌呤標記技術於完整細胞中測量由CRF (人類/大鼠 態）所刺激之環狀AMP累積。在假設拮抗劑（1 〇 # M)或载體^ (二曱基亞砚1%體積）存在下，架構CRF之濃度-反應曲線。 由式KB=[拮抗劑，Μ ]/濃度比例-1 )由對照面線之向右移動 計异ΚΒ值，其中濃度-比例表示存在有拮抗劑之EC枯 /不存在有拮抗劑之CRF £(：5{)值[?1_11^11§(^1:， In ··兒茶驗胺 (由 Blaschko Η 及 Muscholl E 編輯）第 283-335 頁，
第9頁 509689
Springer, Berlin， 1972]。 nM時顯.現 此測試中’本發明藥劑在K b C R F丨值約1至5 〇 〇 C F R!括抗活性。 因此本發明之藥劑可用以治療具增加CRF内源性旦 中ΗΡΑ (下丘腦垂體軸）失調之任何病況，或由二J/或 促成之各種疾病，包含發炎疾病如關節炎， 礼而及過敏； 焦慮包含晋遍性焦慮；恐怖及恐懼侵襲；抑 >r 影，疲勞症候 群；頭痛；疼痛如發炎性或神經性疼痛；病 、 广设姆 ^ ^ ^ , 么症，應激性腸 症候群’包3克隆氏疾病，痙擎性結腸及應激性钟腸· 疫官能障礙；人類免疫缺乏病毒（HI V)感染；抽 1經退化疾 病如老年癡呆、阿茲海默氏疾病及帕金森氏痂 - /六两，Τ風及 頭部外傷；癲癇；胃腸疾病；飲食及體重障礙如嗜食症及 神經性厭食症；出血性應力；藥物及醇戒除症候^ Τ =物 上癮；睡眠障礙；荷爾蒙失調；皮膚障礙；應力誘發^偶 發精神病；生育問題；性官能障礙及早產。 & 本發明藥劑於上述疾病之利用性可以數種測試證實： 例如本發明藥劑之解焦慮活性可以於老鼠升高之走迷宮 加以證實[例如參見Rodgers R.J·，Behavioural Pharmacology 8:4 77-49 6 ( 1 997 )，升高之走迷宮相關性 討論於第486頁；方法則參見Rodger s R· J·等人之 Ethology and Psychopharmacology (SJ Cooper 及CA Hendrie 編輯），第 9-44 頁（1994)，J· Wiley， C h i c h e s ΐ e r ]。此測試中，本發明藥劑在投與0 · 1至3 0毫克 /公斤p . 〇.時顯現似解焦慮活性。 509689 五、發明說明（8) 對上述指示而言，適宜劑量當然視例如所用化合物、宿 主、投藥模式及欲治療病況之性質及嚴重性等而變化 '但 通常對動物以約0 · 1至約1 0 0，較好約0 · 5至約1 0 0毫克/公 斤動物體重之日劑量可獲得令人滿意之結果。對較大哺乳 類中，例如人類中，所示之日劑量為約1至約5 0 0，較好約 1至約3 0 0毫克本發明藥劑，方便每曰分成達4次之劑量投 藥或以持續釋出狀態投藥。 本發明藥劑可以任何習知路徑投藥，尤其腸内，較好口 服例如錠劑或膠囊態，或以注射溶液或懸浮液態非經腸道 投藥。 · 對上述指示而言，較佳化合物為實例1化合物。上述結 合測試中，該化合物以36 nM之Kb CRFi呈現CRF:拮抗活 性。上述升高走迷宮中，0.1至10毫克/公斤p.o.劑量（最 大為3毫克/公斤）明顯影響焦慮相關行為參數。與標準曱 氨二氮草相反，並未影響與動作刺激有關之參數，其表示 所觀察到之解焦慮效果不會造成一般之動作刺激。 依據前述，本發明亦提供本發明藥劑作為醫藥例如用以 治療由CRF誘發或促成之疾病（如上述者）之醫藥用途。 本發明又提供一種含有本發明藥劑及至少一種醫藥載體 或稀釋劑之醫藥組合物。此種組合物可以習知方式製造。 單位劑型含有例如約0 · 2 5至約1 5 0，較好0 . 2 5至約2 5毫克 本發明化合物。 再者本發明提供本發明藥劑用以製造供治療上述任何病 況之醫藥之用途。
第11頁 本發明γ、 療上述住‘進一步目的係提供—種對需此治療之受療者治 本發明藥g病况之方法，包括對受療者投與治療有效量之 下歹眷> γ t 實例1 : 5 σ兒明本务明。溫度為攝氏度且未校正。 啶〜4〜Λί’ 7〜二甲基一4一[2, 5 —二甲基-6-(二正丙基）胺基嘧 含4:]胺基—H3—苯并噻二唑 2, 1，^〜、氣二2, 5一二曱基嘧啶—6—基）胺基-5, 7-二甲基-甲基叫f Β島二嗤（3 · 5克）及二正丙胺（5 · 3 5毫升）之絕對 小時。使°各燒嗣（35毫升）溶液於密封瓶中在157。攪拌96 5 〇毫升次用薄層層析法追蹤反應。冷卻反應混合物，添。加 升）。7 /且水相以曱基第三丁基醚萃取2次（ 2 x20 0毫一 三丁：μ：機相經脫水、蒸發並在石夕膠上使用環己烧/甲基第 醇再鈐曰V D : 1 )層析分離。蒸發適宜之區份且殘留物自甲 士 _ ’ 得標的產物。Mp = 117-119。。 4 7下逃製備起始物4-(4 -氯-2, 5 -二甲基嘧啶-6 -基）胺基 4>67/=二甲基-2，1，3-苯并噻二唑： 升）一甲基〜2, 1，3 —苯并噻二唑（7· 7克）溶於濃硫酸（20毫 ’攪拌下冷卻至0-5。並滴加硝酸（2. 5毫升； 1 · 5 2、 先· y。此透明溶液倒於冰上並濾出所得沉澱及以水， 所得5, 7 -二甲基-4 -硝基-2，1，3 -苯并噻二唑自環己烧 再結晶。Μρ=ι〇5-106。。 5’ 7—二甲·基-4 -硝基-2, 1，3-苯并噻二唑（20克）於水（2· 2 升）及乙醇（2.2升）中溫熱至沸騰並逐次添加連二硫酸 納（強烈放熱反應）。反應混合物立即於冰浴中冷卻及以乙
第12頁
O:\56\56961.PTD 509689 五、發明說明（ίο) 酸乙酯萃取。有機相經蒸發濃縮且殘留物自水中再結晶 得4 -胺基-5, 7 -二甲基-2, 1，3 -苯并噻二唑。 -
Mp-113»114 0 。 克）在氬氣下 喃（50毫升） 接著在3 0分 啶（4克）之絕 溫再授拌1 6小 甲醇洗。自甲 4 -胺基-5, 7-二甲基-2, 1，3 -苯并噻二唑（4 逐次添加至含氫化鈉（2 · 7 2克）之絕對四氫呋 55%分散液中。混合物在25- 30。攪拌3小時 鐘内於5。下滴加含4, 5-二氯-2, 5-二曱基嘧 對四氫呋喃（2 0毫升）溶液。反應混合物在室 時，小心添加冰水。所得沉澱以水洗及少量 基嘧啶_6-秦） 74- 1 77 0 。… 醇或環己烷再結晶後，得4-(4-氯-2, 5 -二甲 胺基-5,7-二曱基-2，1，3-苯并噻二唑。Mp = l 類似於實例1可製得下列式I化合物： a)下式化合物
R6 Rs \ / 5 N
實例 Ri Ri r3 R4 Rs R6 Mp 2 Me Me Me Me 正丙基 -ΟΗ2-環丙基 120-121° 3 Me Me Me H 正丙基 環丙基 124-127° * 4 Me Me Me H 正丙基 正丙基 177-179° * 5 Me Me Me Cl 正丙基 正丙基 106-108° 6 Me Me Me Cl 正丙基 -CHr環丙基 ， 111-113° 7 Me Me Me Me 正丙基_ Et 101-102° 第13頁
509689 五、發明說明（π) 8 Me Me Me Me 正丁基 Et 83-84° * 9 Me Me Me Me -CH2CH2OCH3 -CH2CH2OCH3 70-73° 10 Me Me Me Me -CH2-CH(CH3)-CH3 -CH2-CH(CH3)-CH3 104-105° 11 Me Me Me Me 3-戊基 Η 113-115° 12 Me Me Me Me 2- 丁基 Η 88° 13 Me Me Me CN 正丙基 正丙基 171-173° 14 Me Me Me CN 正丙基 •CHr環丙基 165-167° 15 Cl Cl Me Me Me Et 116° 16 Cl Cl Me Me Me 正丁基 105° 17 Cl Cl Me Me Et Et 189-193°* 18 Cl Cl Me Me Et 正丙基 107° 19 Cl Cl Me Me Et 正丁基 101° 20 Cl Cl Me Me 正丙基 正丙基 118-121° 21 Cl Cl Me Me 正丙基 -CH2」環丙基 120-123° 22 Cl Cl Me Me 正丁基 正丁基 56° 23 Cl Cl Me Me 烯丙基 烯丙基 112° 24 Cl Cl Me Me · Η 苄基 126° 25 Cl Cl Me Me Me 苄基 138° 26 Me Cl Me Me 正丙基 正丙基 102-104° 27 Me Cl Me Me 正丙基 -CHr環丙基 131-132° 28 Cl Me Me Me 正丙基 -CHr環丙基 110-112° 29 Cl Me Me Me 正丙基 正丙基 112-114° 30 Cl H Me Me 正丙基 正丙基 77-80° 31 Me H Me Me 正丙基 正丙基 95-98°
Me=甲基；4 Εΐ=乙基；* :富馬酸鹽 11·· 第14頁 509689 五、發明說明（12) b )下式化合物
R6 R. \ / 5 N
實例 Ri Ri r3 R4 Rs ^6 Mp 32 Me Me Me Me 正丙基 正丙基 123° 33 Cl Me Me Me 正丙基 正丙基 100° 34 Me Me Me Me 正丙基 -CH〗-環丙基 < 105° - 35 Cl Me Me Me 正丙基 -CHr環丙基 86° 36 Me Me Me Me 正丙基 Et 102〇 37 Me Me Me Me 正丁基 Et 71°
Me=曱基；Et=乙基 c )下式化合物
R6 R5 \ / 5 N
胥例 Ri Ri r3 R4 Rs r6 Mp 38 Me Me Me Me 丙基 正丙基 94-96° 39 Cl Cl Me Me 正丙基 _ 正丙基1 126-128° 40 Cl Me Me Me 正丙基 丨正丙基 ，. 107-109° 509689 五、發明說明（13) 41 C1 Me Me Me 正丙基 -CH2-環丙基 115-117° 42 Me Me Me Me 正丙基 -CHr環丙基 105406， 43 Cl Cl Me Me 正丙基 -CH2-環丙基 126-127° 44 Cl Cl Me Me Et 正丙基 120-123° 45 Me Me Me Me Et 正丙基 109-110° 46 Cl Cl Me Me Et 正丁墓· 117-119° 47 Me Me Me Me Et 主丁墓 106-107°
Me=甲基；Et二乙基 d )下式化合物 R5 \ / 5
實例 X Ri R3 r4 Rs R. Mp 48 S Cl Me Me Et 正丁基 85° 49 S Cl Me Me 正丙基 -CH〗-環丙基 84° 50 CH=CH Br Me Me Et 正丁基 110° 51 CH=CH Br Me Me 正丙基 -CH2-環丙基 135°
Me二甲基；Et=乙基
Hill 第16頁 509689 五、發明說明（14) e)下式化合物
r2 ^Ν、 V 實例 X Ri r2 R3 R5 R6 r7 Rb Mp 52 S Me Me Me Et 正丁基 Me Me 90-92° 53 CH=CH Me Me Me Et 正丁基 Me .， Me 106-108° 54 S Me Me Me 正丙基 正丙基 Me Me 126-128° · 55 CH=CH - Me Me Me 正丙基 正丙基 Me Me 156-158° 56 S Cl Me Me 正丙基 正丙基 Me Me 135-136° 57 CH=CH Cl Me Me 正丙基 正丙基 Me Me 130-131° 58 S Cl Me Me Et 正丁基 Me Me 90-92° 59 CH=CH Cl Me Me Et 正丁基 Me Me 177-178°
Me=曱基；Et=乙基 f )下式化合物 實例 Ri Ri Rs R6 Mp 60 Me Me 正丙基 -CHr環丙基 234-237° *
Me=甲基；* :富馬酸鹽
第17頁 509689 案號88102726 f年I月丨Ί曰 修正
O:\56\56961.ptc 第18頁

Claims (1)

  1. 509689 修正 案號 88102726 六、申請專利範圍 1 . 一種呈游離鹼或酸加成鹽態之式I化合物
    公1告象 其中 X 為0，S，或CH = CH， I及1獨立為氫、鹵素或（(^_4)烷基；及 Het為具下式（a)，（e)，及（m)之一之基 NH
    ^6 (a) R5
    (c) R6、
    (m) 其中 R3為（Ch)烧基， R4為氫、鹵素、（c^)烷基、鹵素或氰基， R5及^獨立為氫、（Ch)烷基、（c3_7)烯基、（c3_7)環烷 基（Ch)烷基或烷氧基（C2-5)烷基， R7為（Ch)烷基，及 R8為（Ch)烷基。
    O:\56\56961.ptc 第19頁 509689 案號 88102726 曰 修正 t、申請專利範圍 2. —種呈游離鹼或酸加成鹽態之5, 7 -二甲基_4-[ 2, 5-二 甲基-6-(二正丙基）胺基嘧啶-4 -基]胺基-2, 1，3-苯并噻二 口全 ° 3 · —種製備根據申請專利範圍第1項之式I化合物或其鹽 之方法，包括使式I I化合物： R,
    N. 其中X，Ri及1?2如申請專利範圍第1項之定義，及Y為具 下式（a’），（e’），及（m’）之一之基： NH
    (Ο Hal
    (Ο Hal
    (η〇 其中R3至1係如申請專利範圍第1項之定義及Hal為鹵 素；與式I I I化合物在有機溶劑中，溫度範圍在1 0 0至2 0 0 °C下反應，反應時間1至5天： in R<
    O:\56\5696l.ptc 第20頁 509689 _案號88102726_丨年I月1Ί日 修正_ 六、申請專利範圍 其中R5 &R6如申請專利範圍第1項之定義；及使所得化 合物轉化成游離驗態或酸加成鹽態。 4.根據申請專利範圍第1或2項之呈游離鹼或酸加成鹽態 之化合物，其係作為醫藥品。 5 .根據申請專利範圍第1或2項之呈游離鹼或酸加成鹽態 之化合物，其係用於治療具增加内源性量之CRF或其中ΗΡΑ 失調之任何狀態或治療由CRF誘發或促成之疾病。 6. —種用於治療具增加内源性量之CRF或其中ΗΡΑ失調之 任何狀態或治療由CRF誘發或促成之疾病之醫藥組合物， 其包括根據申請專利範圍第1或2項之呈游離鹼或酸加成鹽 態之化合物以及醫藥載體或稀釋劑。
    O:\56\5696i.ptc 第21頁
TW088102726A 1998-02-03 1999-02-24 Benzothiadiazoles and derivatives TW509689B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9802251.0A GB9802251D0 (en) 1998-02-03 1998-02-03 Organic compounds

Publications (1)

Publication Number Publication Date
TW509689B true TW509689B (en) 2002-11-11

Family

ID=10826354

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088102726A TW509689B (en) 1998-02-03 1999-02-24 Benzothiadiazoles and derivatives

Country Status (29)

Country Link
EP (1) EP1049694B1 (zh)
JP (1) JP3455180B2 (zh)
KR (2) KR100507250B1 (zh)
CN (1) CN1119346C (zh)
AR (1) AR015222A1 (zh)
AT (1) ATE217622T1 (zh)
AU (1) AU745051B2 (zh)
BR (1) BR9909739A (zh)
CA (1) CA2318977A1 (zh)
CO (1) CO4990932A1 (zh)
DE (1) DE69901483T2 (zh)
DK (1) DK1049694T3 (zh)
ES (1) ES2178451T3 (zh)
GB (1) GB9802251D0 (zh)
HU (1) HUP0100978A3 (zh)
ID (1) ID26156A (zh)
IL (1) IL137332A (zh)
MY (1) MY122453A (zh)
NO (1) NO316913B1 (zh)
NZ (1) NZ505970A (zh)
PE (1) PE20000246A1 (zh)
PL (1) PL194838B1 (zh)
PT (1) PT1049694E (zh)
RU (1) RU2219177C2 (zh)
SK (1) SK283833B6 (zh)
TR (1) TR200002237T2 (zh)
TW (1) TW509689B (zh)
WO (1) WO1999040089A1 (zh)
ZA (1) ZA99800B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
GB0302876D0 (en) * 2003-02-07 2003-03-12 Novartis Ag Organic compounds
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007149938A2 (en) 2006-06-21 2007-12-27 The Salk Institute Biological Studies Methods for promoting hair growth
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
KR102571296B1 (ko) * 2016-09-07 2023-08-28 더 리전트 오브 더 유니버시티 오브 캘리포니아 P-tau를 감소시키고 인지를 개선하는 알로스테릭 코르티코트로핀-방출 인자 수용체 1 (crfr1) 길항제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
TW241263B (zh) * 1991-08-22 1995-02-21 Hoechst Roussel Pharma
CA2118138A1 (en) * 1992-04-28 1993-10-29 Minoru Okada Novel substituted tertiary amino compound or salt thereof
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives

Also Published As

Publication number Publication date
IL137332A (en) 2005-11-20
AR015222A1 (es) 2001-04-18
CN1119346C (zh) 2003-08-27
KR20040097226A (ko) 2004-11-17
ATE217622T1 (de) 2002-06-15
WO1999040089A1 (en) 1999-08-12
KR100507250B1 (ko) 2005-08-10
GB9802251D0 (en) 1998-04-01
AU745051B2 (en) 2002-03-07
SK283833B6 (sk) 2004-03-02
CO4990932A1 (es) 2000-12-26
RU2219177C2 (ru) 2003-12-20
PL194838B1 (pl) 2007-07-31
JP3455180B2 (ja) 2003-10-14
PT1049694E (pt) 2002-09-30
SK11572000A3 (sk) 2001-02-12
IL137332A0 (en) 2001-07-24
PL342008A1 (en) 2001-05-07
AU3252199A (en) 1999-08-23
KR100502880B1 (ko) 2005-07-21
PE20000246A1 (es) 2000-05-15
KR20010040550A (ko) 2001-05-15
EP1049694B1 (en) 2002-05-15
JP2002502853A (ja) 2002-01-29
CA2318977A1 (en) 1999-08-12
DE69901483T2 (de) 2002-10-31
MY122453A (en) 2006-04-29
HUP0100978A3 (en) 2003-08-28
ZA99800B (en) 1999-08-03
ID26156A (id) 2000-11-30
TR200002237T2 (tr) 2000-12-21
CN1289334A (zh) 2001-03-28
NZ505970A (en) 2003-03-28
EP1049694A1 (en) 2000-11-08
ES2178451T3 (es) 2002-12-16
NO20003916D0 (no) 2000-08-02
NO20003916L (no) 2000-09-28
DK1049694T3 (da) 2002-09-09
HK1033578A1 (zh) 2001-09-07
HUP0100978A2 (hu) 2002-05-29
DE69901483D1 (de) 2002-06-20
BR9909739A (pt) 2001-03-20
NO316913B1 (no) 2004-06-21

Similar Documents

Publication Publication Date Title
JP7530360B2 (ja) Ｔｙｋ２阻害剤およびその使用
KR100507250B1 (ko) 벤조티아디아졸 및 유도체
CN1060768C (zh) 吡唑和吡唑并嘧啶
CN102216300B (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN109415361B (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2016094688A1 (en) Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
JPH06510287A (ja) ムスカリン作用物質
CN103717593B (zh) 调节激酶的组合物和方法
JPH09500908A (ja) ジヒドロピラゾロピロール類
CN112041307B (zh) 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
US10017458B2 (en) Therapeutic tetrahydronaphthalene compounds
IL300352A (en) The compositions for cutting and fusion modulation
WO2022206705A1 (zh) 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
TW200526625A (en) Pharmaceutically active compounds
JP2006516981A (ja) Ｃｒｆ−アンタゴニストとしてのベンゾ（１，２，５）チアジアゾール
JP2024511518A (ja) ピラゾロピリミジノン化合物
US6756367B2 (en) Benzo-oxadiazoles, -thiadiazoles and -1,4-diazines, pharmaceutical compositions containing them and a process for preparing them
CN105431146B (zh) 2-卤代-5-炔基-吡啶基烟碱性配体
TWI681960B (zh) 苯并咪唑類衍生物及其製備方法及其在醫藥上的用途
CZ20002809A3 (cs) Benzothiadiazoly a jejich deriváty, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
MXPA00007623A (en) Benzothiadiazoles and derivatives
WO2023091550A1 (en) Methods of treating estrogen receptor-associated diseases
CN118221633A (zh) 一种trpv1/urat1双重抑制剂、其制备方法及应用
HK1033578B (zh) 苯并恶二唑，苯并噻二唑，苯并三唑和喹喔啉的衍生物
JP2010536918A (ja) モノアミン再取り込み阻害剤として用いるための置換アザビシクロ［４．１．０］ヘプタン化合物

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees